ChiCTR2000033627尚未招募Unknown
In vivo use of ivermectin (IVR) for treatment for corona virus infected patients: a randomized controlled trial
黎巴嫩大学2 个研究点 分布在 2 个国家目标入组 60 人开始时间: 2020年6月10日最近更新:
干预措施
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Reduction of viral load and treating COVID-19 infection
研究概览
简要总结
The objectives of the study are to test if:
- Ivermectin is an effective treatment for COVID-19 infected patients;
- Ivermectin will reduce significantly viral load within 72 hours of its administration to COVID-19 infected patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- 随机平行对照
入排标准
- 性别
- All
入选标准
- •Adults with positive PCR for COVID-19 (asymptomatic for the Pilot intervention);
- •Body weight more than 45kg;
- •Consent for voluntary participation.
排除标准
- •Patients with end stage heart failure;
- •Recent cardiac intervention (less than 2 months): coronary angioplasty, ICD, CABG, Valvuloplasty or replacement;
- •Pulmonary fibrosis or advanced COPD;
- •End stage kidney or liver disease;
- •Pregnant or lactating ladies;
- •Patients on immunosuppressive therapy;
- •Active tuberculosis;
- •Active hepatitis;
- •Patients requiring planned blood transfusion (Thalasemia major, aplastic anemia).
研究组 & 干预措施
2
伊维菌素
干预措施: 伊维菌素
1
Placebo
结局指标
主要结局
Reduction of viral load and treating COVID-19 infection
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
2 期
To compare the efficacy and safety profile of topical ivermectin versus topical metronidazole in patients with side effects like red-raised or pus-filled lesions, redness, itching, burning sensation, etc due to long-term use of topical steroid on face in a tertiary care teaching hospital.CTRI/2024/12/078264Dr CHIRAG SAINI120
尚未招募
1 期
the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts.NCT07396714Assiut University88
招募中
2 期
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 PatientsImmunodeficiencyNCT07406217Calmy Alexandra256
招募中
3 期
A Study to Learn About a Study Medicine Called Ibuzatrelvir in People With Coronavirus Disease 2019 (COVID-19) and a Severely Compromised Immune System2024-517671-21-00Pfizer Inc.94
Unknown
不适用
评价依奇珠单抗联合常规抗病毒药物治疗新型冠状病毒肺炎(COVID-19)患者的有效性和安全性的随机盲法对照多中心临床试验ChiCTR2000030703国家级课题项目40